Patient Square Capital LP Acquires 120,507 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Patient Square Capital LP grew its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 37.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 446,296 shares of the company's stock after purchasing an additional 120,507 shares during the quarter. Nurix Therapeutics makes up approximately 3.1% of Patient Square Capital LP's holdings, making the stock its 6th biggest holding. Patient Square Capital LP owned about 0.59% of Nurix Therapeutics worth $8,408,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NRIX. US Bancorp DE boosted its stake in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Nurix Therapeutics in the fourth quarter valued at about $87,000. Summit Investment Advisors Inc. lifted its stake in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after buying an additional 877 shares during the period. BNP Paribas Financial Markets bought a new position in Nurix Therapeutics during the fourth quarter worth about $164,000. Finally, Nomura Holdings Inc. bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $198,000.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Leerink Partners initiated coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Stephens reaffirmed an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, Royal Bank of Canada boosted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,438 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $28,037.00. Following the transaction, the chief financial officer now owns 39,922 shares in the company, valued at approximately $459,103. This trade represents a 5.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,838 shares of company stock worth $221,500 in the last quarter. 7.40% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Trading Down 4.4%

NASDAQ NRIX opened at $9.73 on Wednesday. The stock has a 50 day moving average of $11.32 and a 200-day moving average of $17.18. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The company has a market cap of $741.78 million, a PE ratio of -3.37 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The company had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period last year, the firm posted ($0.76) earnings per share. As a group, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.